Open Access

Impact of different diagnostic technologies for MRSA admission screening in hospitals – a decision tree analysis

  • Claudia Hübner1Email author,
  • Nils-Olaf Hübner2, 3,
  • Christian Wegner2 and
  • Steffen Flessa1
Antimicrobial Resistance and Infection Control20154:50

DOI: 10.1186/s13756-015-0093-0

Received: 3 July 2015

Accepted: 12 November 2015

Published: 3 December 2015

Abstract

Background

Hospital infections with multiresistant bacteria, e.g., Methicillin-resistant Staphylococcus aureus (MRSA), cause heavy financial burden worldwide. Rapid and precise identification of MRSA carriage in combination with targeted hygienic management are proven to be effective but incur relevant extra costs. Therefore, health care providers have to decide which MRSA screening strategy and which diagnostic technology should be applied according to economic criteria.

Aim

The aim of this study was to determine which MRSA admission screening and infection control management strategy causes the lowest expected cost for a hospital. Focus was set on the Point-of-Care Testing (PoC).

Methods

A decision tree analytic cost model was developed, primarily based on data from peer-reviewed literature. In addition, univariate sensitivity analyses of the different input parameters were conducted to study the robustness of the results.

Findings

In the basic analysis, risk-based PoC screening showed the highest mean cost savings with 14.98 € per admission in comparison to no screening. Rapid universal screening methods became favorable at high MRSA prevalence, while in situations with low MRSA transmission rates omission of screening may be favorable.

Conclusion

Early detection of MRSA by rapid PoC or PCR technologies and consistent implementation of appropriate hygienic measures lead to high economic efficiency of MRSA management. Whether general or targeted screening is more efficient depends mainly on epidemiological and infrastructural parameters.

Keywords

Admission screening Point-of-care Hospital Cost Decision tree analysis Methicillin-resistant Staphylococcus aureus

Background

Infections with Methicillin-resistant Staphylococcus aureus (MRSA) cause heavy financial burden on healthcare systems worldwide [13]. In particular, hospitals are highly economically affected by the consequences [4]. About 5 % of all hospital-acquired infections are caused by MRSA [5]. Main cost drivers are prolongation of hospital stay and contact precaution measures [6]. While the economic impact on nosocomial MRSA acquisition is controversial, it has been proven that rapid and precise identification of MRSA carriage at hospital admission reduces turn-around-time and thus the number of days in precautionary isolation [7, 8].

Health care providers have to decide which screening strategy to follow and which diagnostic technology to use in consideration of medical and economic criteria. The three main strategic options are universal screening, targeted risk-based screening or the omission of screening. Polymerase-Chain-Reaction (PCR), culture and Point-of-Care (PoC) methods are the diagnostic technologies available on the market [9].

Several screening strategies have been studied in terms of their cost-effectiveness [1012]. However, little is known about the impact of the concrete implementation of a diagnostic test system in an MRSA hygiene management of a hospital. Aim of this study was to determine which MRSA screening and management strategy causes the lowest expected cost for a hospital with special focus on PoC technology, a relatively new technology that is not yet widely used for MRSA screening management.

Methods

Analytical model

The analysis is based on a multi-stage decision model that assesses the expected cost of alternative MRSA admission screening and infection control management strategies. The decision tree developed for this purpose is shown in Fig. 1. The first branch is the decision between “no screening” and “screening”. Here, the hospital has to decide whether a screening strategy will be implemented or not. If a screening is conducted, it must be decided whether universal or targeted screening should be applied. Universal screening means that all patients admitted to the hospital are screened for MRSA. Targeted screening includes only high risk patients. In Germany, the Commission for Hospital Hygiene and Infection Prevention (KRINKO) gives recommendations on risk factors (e.g., known MRSA patient history, previous hospitalization in the last 12 months, contact with animal farms, chronic care, previous antibiotic therapy in the last 6 months) [13]. According to these recommendations, health facilities can define additional factors based on individual risk assessment. Further branches model the chosen test method (PoC, PCR or culture methods) and whether patients are taken under isolation while waiting for test results (pre-emptive isolation).
Fig. 1

Model structure of the decision tree: 4-step-approach with decisions to (1) screening or not screening, (2) universal or targeted screening of high risk patients, (3) PoC, PCR or culture test and (4) pre-emptive isolation or no pre-emptive isolation

Finally the following 11 strategies were derived:
  • no screening,

  • universal screening with PoC testing (cultural confirmation of positive test results),

  • universal screening with cultural testing and pre-emptive isolation,

  • universal screening with cultural testing and without pre-emptive isolation,

  • universal screening with PCR testing (cultural confirmation of positive test results) and pre-emptive isolation until PCR result,

  • universal screening with PCR testing (cultural confirmation of positive test results) and without pre-emptive isolation,

  • targeted screening of high risk patients with PoC testing (cultural confirmation of positive test results),

  • targeted screening of high risk patients with cultural testing and pre-emptive isolation,

  • targeted screening of high risk patients with cultural testing and without pre-emptive isolation,

  • targeted screening of high risk patients with PCR testing (cultural confirmation of positive test results) and pre-emptive isolation until PCR result,

  • targeted screening of high risk patients with PCR testing (cultural confirmation of positive test results) and without pre-emptive isolation.

Input parameter

As shown in Table 1, most data were taken from a previous literature review conducted by our working group [14]. Values regarding the cross-transmission rates have been updated by reassessment of the literature: RTno iso (new: 0.0443, old: 0.01), RTiso (new: 0.0033, old: 0.0029). The data of two more studies [15, 16] have been incorporated, as they are examples of higher cross-transmission rates, especially in situation without isolation, which were previously in [14] under-represented. Other data are based on in-house references of the University Medicine of Greifswald (UMG) and Mölnlycke Health Care.
Table 1

Definition and quantification of input parameter

Parameter

Description

Value

Reference

P t

MRSA prevalence of all inpatients

3.075 %

[14]

P r

MRSA prevalence of high-risk inpatients

11.94 %

[14]

P n. i.

MRSA prevalence of patients without indication for a targeted screening

2.09 %

Calculation based on in-house data (UMG)a

RT no iso

Rate of MRSA transmission not in isolation per day

0.0443

[14], updated with [15, 16]

RT iso

Rate of MRSA transmission in isolation per day

0.0033

[14], updated with [15, 16]

Sen PoC

Sensitivity of PoC method

95 %

In-house data (mölnlycke hc)

Sen PCR

Sensitivity of PCR method

91.09 %

[14]

Sen cul

Sensitivity of culture method

88.73 %

[14]

SP PoC

Specificity of PoC method

97.5 %

In-house data (mölnlycke hc)

SP PCR

Specificity of PCR method

95.79 %

[14]

SP cul

Specificity of culture method

93.23 %

[14]

C pre iso

Average costs for pre-emptive isolation per day

62.77 €

[14]

C MRSA

Average costs per MRSA case per day

506.92 €

[14]

 LOS MRSA

Average length of stay of MRSA patients in days

24.88

[14]

T PoC

Turn-around time of PoC method in days

0.01389

[9]

T PCR

Turn-around time of PCR method in days

0.29

In-house data (UMG)

T cul

Turn-around time of culture method in days

2.5

In-house data (UMG)

C PoC

Costs for a single PoC test

30 €

[9]

C PCR

Costs for a single PCR test

20.50 €

[14]

C cul pos

Costs for a single culture test with positive result

24.10 €

[14]

C cul neg

Costs for a single culture test with negative result

6.40 €

[14]

C f

Costs for follow-up screening

6.40 €

Costs of a negative culture test are assumed

C c

Costs for screening a contact patient

6.40 €

Costs of a negative culture test are assumed

Pat c

Number of contact patients

2

calculation based on in-house data (UMG)

 LOS reg

Average length of stay of regular patients in days

8

[14]

Pat t

Number of total inpatients per year

35,322

In-house data (UMG)

Pat risk

Number of high-risk patients per year

3,532

In-house data (UMG)

Pat n. i.

Number of patients without indication for a targeted screening per year

31,790

In-house data (UMG)

a UMG University Medicine Greifswald

Assumptions

For the analytical model, several assumptions have been made:
  1. 1.

    Positive MRSA test results by PCR or PoC but must be confirmed by a culture test.

     
  2. 2.

    Negative MRSA test results by PCR or PoC will not be confirmed by a culture test.

     
  3. 3.

    If the MRSA test is negative, pre-emptive isolation is immediately discontinued and no further steps are taken.

     
  4. 4.

    Due to the short turn-around-time of the PoC test no pre-emptive isolation is taken into account.

     
  5. 5.

    Decision tree branches end after MRSA is excluded or after MRSA eradication treatment and follow-up screening has been conducted.

     
  6. 6.

    Cultural test method is applied for follow-up and contact-patient screening. These test results assumed to be negative.

     
  7. 7.

    Secondary MRSA cases (due to transmission events from index patients) are included in the analysis and causes costs of MRSA infections.

     
  8. 8.

    Tertiary MRSA cases (due to transmission events from secondary patients) are not included in the analysis.

     
  9. 9.

    Screening of contact persons is only necessary if no pre-emptive isolation of MRSA patient is conducted.

     

Cost calculation

Expected costs for each screening strategy are calculated in the decision model. Calculations are based on the values of input parameters stated in Table 1. The principle is demonstrated exemplary for targeted PCR screening with pre-emptive isolation measures by the following formulas of Table 2.
Table 2

Calculation of expected costs in decision model (using the example of strategy “targeted PCR screening with pre-emptive isolation measures”)

Combinations of true and tested MRSA status of screened patients

Costs per patient*:

Number of patients*:

MRSA positive

C PCR + C culpos + C preiso * (T PCR + T cul ) + C MRSA * (Ø LOS MRSA - T PCR -T cul ) + C c *Pat c + Ø LOS MRSA * RT iso * C MRSA * Ø LOS MRSA

Pat risk * P risk * Sen PCR * Sen cul

 PCR (+) and culture (+) → true positive

MRSA negative

C PCR + C culpos + C preiso * (T PCR + T cul ) + C MRSA * (Ø LOS MRSA - T PCR -T cul ) + C c *Pat c

Pat risk * (1 - P risk ) * (1 - SP PCR ) * (1 - SP cul )

 but PCR (+) and culture (+) → false positive

MRSA positive

C PCR + C culneg + C preiso * (T PCR + T cul ) + [(Ø LOS MRSA - T PCR -T cul ) * RT noiso + (T PCR + T cul ) * RT iso ] * C MRSA * Ø LOS MRSA

Pat risk * P risk * Sen PCR * (1 - Sen cul )

 PCR (+), no confirmation because culture (-) → false negative

MRSA negative

C PCR + C culneg + C preiso * (T PCR + T cul )

Pat risk * (1 - P risk ) * (1 - SP PCR ) * SP cul

 PCR (+), no confirmation because culture (-) → false positive

MRSA positive

C PCR + C preiso * T PCR + [(Ø LOS MRSA - T PCR ) * RT noiso * + T PCR * RT iso ] * C MRSA * Ø LOS MRSA

Pat risk * P risk * (1 - Sen PCR )

 but PCR (-), no culture test conducted → false negative

MRSA negative

C PCR + C preiso * T PCR

Pat risk * (1 - P risk ) * SP PCR

 PCR (-), no culture rest conducted → true negative

No high-risk patients (screening is not indicate)

Cost due to transmission (of MRSA-Patients, who were not screened)

Number of patients

 MRSA positive

Ø LOS MRSA * RT noiso * C MRSA * Ø LOS MRSA

Pat n.i. * P n.i.

 MRSA negative

no costs

Pat n.i. * (1-P n.i. )

*note: Variables are explained in Table 1

Additionally, cost differences of each strategy to the counterfactual strategy "no screening" were determined per admission to compare all screening strategies. Advantageous screening strategies resulted in cost savings (positive net benefit), unfavorable screening strategies in additional costs.

Sensitivity analyses

Univariate sensitivity analyses of the parameters “Rate of nosocomial MRSA transmission” and “MRSA prevalence” were conducted. This allows simulating scenarios of hospitals with various structure and patient profiles (primary care vs. specialist care), departmental analyses (ICUs vs. general wards) or the consideration of MRSA outbreak situations.

MRSA transmission rate not in isolation was varied between 0.001 and 0.121 transmission per day. A division of each varied value by the factor 13 determined the corresponding values of MRSA transmission rate in isolation. This ratio of 1:13 resulted as the average of all included references (Table 1).

With regard to MRSA prevalence, an interrelation between the parameters “MRSA prevalence of all inpatients” and “MRSA prevalence of high-risk inpatients” is implied. Therefore, three scenarios at different MRSA prevalences (all inpatients/high-risk inpatients) were tested: low prevalence (0.5 %/3.5 %), middle prevalence (3.08 %/11.94 %) and high prevalence (7.5 %/25 %).

Results

Basic analysis

Targeted MRSA screening and hygiene management regimes using PoC or PCR technologies proved to be the most cost minimizing strategies in basic analysis. Average costs of all three methods were calculated between 468 and 470 € per admission. Strictly, risk-based (targeted) PoC screening showed the highest cost saving with a net benefit of 14.98 € per admission compared to “no screening”. However, deviations between the different screening regimes were quite moderate with the exception of universal cultural test methods. Cultural testing in combination with or without pre-emptive isolation caused immensely higher costs per admission compared to the omission of any MRSA-screening with additional costs of 264.40 € (no pre-emptive isolation) or 449.81 € (pre-emptive isolation) per admission, respectively (Table 3).
Table 3

Results of basic analysis for all 11 screening strategies: average costs per admission and cost savings (net benefits) in comparison to strategy “no screening”

Screening strategy

Average cost per admission

Cost-saving to "no screening"a

PoC (target)

468.14 €

−14.98 €

PCR (target, no isolation)

469.30 €

−13.82 €

PCR (target, isolation)

469.80 €

−13.32 €

Culture (target, no isolation)

501.66 €

18.54 €

Culture (target, isolation)

506.90 €

23.78 €

No screening

483.12 €

0.00 €

PoC (universal)

478.18 €

−4.94 €

PCR (universal, no isolation)

478.75 €

−4.37 €

PCR (universal, isolation)

500.07 €

16.95 €

Culture (universal, no isolation)

741.36 €

258.24 €

Culture (universal, isolation)

925.93 €

442.81 €

aA negative value indicates a positive net benefit

Sensitivity analyses

Rate of MRSA transmission

Curves representing the cost of the different screening regimes independence rates of nosocomial MRSA transmission not in isolation between 0.001 and 0.121 per day are shown in Fig. 2. The average cost per admission rises continuously with the increase of the MRSA transmission rate in all screening strategies. Three intervals depending on nosocomial MRSA transmission rate can be distinguished: Below a transmission rate of 0.04322 transmissions per day the omission of any screening method is the least costly strategy. Rapid (PoC or PCR) targeted screening regimens are most advantageous between a rate of 0.04322 and 0.05038 transmissions per day. This span corresponds to the range of MRSA transmission rates of normal wards in hospitals in Central Europe [17]. Universal rapid screening regimens conducted by PoC or PCR cause the lowest cost for a hospital above a transmission rate of 0.05038. This range can be assigned to high-risk areas in hospitals such as intensive care units or to outbreak situations [15, 18].
Fig. 2

Sensitivity analysis: Graph of average cost per admission at different rates of MRSA transmission per day without isolation from 0.001 to 0.121 (corresponding rates of MRSA transmission per day in isolation from 0.0001 to 0.0093)

MRSA prevalence

Differences in the favorability of the specific diagnostic technologies for the three scenarios with low, medium and high MRSA prevalence are shown in Fig. 3. While at a low MRSA prevalence only rapid targeted screening strategies were beneficial versus “no screening”, ever more regimes became advantageous with increasing MRSA prevalence. At a high MRSA prevalence, 7 of 10 strategies are favorable. Here, “universal PoC screening” showed the highest cost savings with 77.22 € per admission compared to “no screening”, followed by the two universal PCR methods (with and without pre-emptive isolation measures).
Fig. 3

Scenario analysis: Column chart of average cost savings per admission in comparison to strategy “no screening” at 3 different MRSA prevalence scenarios (first value indicates prevalence of all patients, second value indicates prevalence of high risk patients)

Discussion

The study shows a decision tree analysis to evaluate various MRSA admission screening methods as part of hygiene management regimes in hospitals. To our best knowledge, Point-of-Care technology is included in such an analytic model for the first time. Our results determine that rapid test methods (PoC or PCR) are always cost-minimizing in comparison to culture methods. By contrast, the decision on a universal or a risk-based method or the omission of any screening is highly dependent on epidemiological and infrastructural conditions regarding healthcare providers.

The MRSA cross transmission rate per day has been found as a very influential parameter by the sensitivity analysis. Based on the literature review of Tübbicke et al. [14] the basic analysis was calculated with an average transmission rate of 0.0443 transmissions per day. This coincides with the mid-interval of our sensitivity analysis (Fig. 3), in which the selective PoC strategy is most cost effective. However, the literature analysis shows outliers to both sides. For example, Raboud et al. [19] declared a very low rate of 0.00137 transmissions per day, while Jernignan et al. [18] showed a significantly higher rate with 0.140 transmissions per day. The latter study has been conducted with the particular patient clientele of neonatology. Other studies with a high cross transmission rate analyse outbreaks of MRSA [15, 16, 18]. Our study results demonstrate that in defined hospital departments (e.g., neonatology, ICUs, oncology, transfusion medicine, burn units) or in outbreak situations universal screening is not only medically but also economically viable.

Variations of MRSA prevalence have also strongly influenced test results. An increase of the MRSA prevalence tends to favor universal screening strategies, while in situations at lower prevalence (basic analysis) targeted risk-based methods are preferable. In line with literature, this underlines the regional epidemiology as an important decision [10]. In most of these studies, authors concluded risk-based screening to be cost-effective. Creamer et al. proved their statement in a backward stepwise logistic regression model by identifying defined risk factors [20]. Bühlmann et al. justified the restricted use of PCR methods with high costs and thus limited the implementation of pre-emptive isolation measures to high risk patients [21]. However, they also acknowledged that it might be different in settings with higher MRSA prevalence and transmission rates as shown in our sensitivity analyses. Shenoy et al. concluded from their randomized controlled trial that active PCR screening leads to a rapid discontinuation of contact precautions for MRSA, which can alleviate capacity constraints [22]. At the same time the authors also stressed that the net benefit of a screening program might depend on institutional characteristics including MRSA prevalence.

Our analysis also illustrates that the price of the test systems is not decisive. In contrast, the admission screening must be evaluated as part of all hygienic processes of a hospital. Early detection of MRSA by PoC or PCR diagnostics with their short turn-around-times and the consistent implementation of appropriate measures result in a high economic efficiency of MRSA management. Consequently, screening strategies with the cheaper culture methods prove comparatively unfavorable due to long turn-around times.

Our study has several limitations. First, the data quality needs to be critically examined. Most data was based on published international studies collected by a systematic literature research. For parameter where no sufficient information was found in the literature, we supplemented in-house data or made assumptions in consultation with hygiene experts. No probabilistic multivariate sensitivity analysis was performed. Instead, robustness of test results was proven by univariate sensitivity analyses and pointed to the dependence of individual parameters. Our analysis includes only transmissions from index patients to secondary cases, while transmissions from secondary cases and so on were excluded, thus underestimating the costs of transmissions. On the other hand, we assumed that all secondary cases cause costs due to MRSA infection for the hospital. Again, this is a simplification that may overestimate costs of transmission.

We did not simulate the effect of pre-test factors that may influence the sensitivity of the screening, e.g., use of different swabs or multi-site swabbing. The literature demonstrates that additional MRSA screening at extra-nasal sites increases MRSA detection by one-third compared to nares screening alone [23]. However, most PCRs and PoCs are not validated for multi-site testing and KRINKO recommendations favor nasal screening. For this reason, we have limited our model on the nares screening.

Finally, the analysis was conducted from the perspective of the healthcare provider and assessed its expected costs. A macroeconomic analysis may come to different statements, since more cost and benefit effects of patients or health insurances must be included. An important preliminary work for this purpose is the computer simulation study by Lee et al., which determined the economic impact of the implementation of a universal MRSA surveillance from the societal and third party-payer perspectives [12]. The extension of the analytical model is a potential research question for future work, especially in terms of inter-institutional cooperation between different healthcare providers and the economic evaluation of pre-admission MRSA screening.

Conclusion

In summary, we developed an analytical model as decision-making tool that allows recommendations for the implementation of a cost-effective MRSA admission screening and infection control management strategy. Obviously, the results demonstrate the economic advantageousness of modern MRSA diagnostic techniques, particularly the Point-of-Care technology. However, it is clear that there is no silver bullet of uniform screening management, but that the knowledge of individual epidemiological and infrastructure parameters of the whole hospital or specific areas is crucial.

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Institute of Health Care Management, University of Greifswald
(2)
Institute of Hygiene and Environmental Health, University Medicine of Greifswald
(3)
IMD laboratory network, MVZ Greifswald GmbH

References

  1. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med. 2013;173(21):1970–8.PubMedGoogle Scholar
  2. de Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8(10), e1001104.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41):19688.PubMedGoogle Scholar
  4. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166–74.View ArticlePubMedGoogle Scholar
  5. ECDC. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. 2011-2012. http://ecdc.europa.eu/en/publications/Publications/healthcare-associated-infections-antimicrobial-use-PPS.pdf.
  6. Hubner C, Hubner NO, Hopert K, Maletzki S, Flessa S. Analysis of MRSA-attributed costs of hospitalized patients in Germany. Eur J Clin Microbiol Infect Dis. 2014;33(10):1817–22.View ArticlePubMedGoogle Scholar
  7. Polisena J, Chen S, Cimon K, McGill S, Forward K, Gardam M. Clinical effectiveness of rapid tests for methicillin resistant Staphylococcus aureus (MRSA) in hospitalized patients: a systematic review. BMC Infect Dis. 2011;11:336.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Roisin S, Laurent C, Denis O, Dramaix M, Nonhoff C, Hallin M, et al. Impact of rapid molecular screening at hospital admission on nosocomial transmission of methicillin-resistant Staphylococcus aureus: cluster randomised trial. PLoS One. 2014;9(5), e96310.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Sturenburg E. Rapid detection of methicillin-resistant Staphylococcus aureus directly from clinical samples: methods, effectiveness and cost considerations. Ger Med Sci. 2009;7:Doc06.PubMed CentralPubMedGoogle Scholar
  10. Farbman L, Avni T, Rubinovitch B, Leibovici L, Paul M. Cost-benefit of infection control interventions targeting methicillin-resistant Staphylococcus aureus in hospitals: systematic review. Clin Microbiol Infect. 2013;19(12):E582–593.View ArticlePubMedGoogle Scholar
  11. Tubbicke A, Hubner C, Hubner NO, Wegner C, Kramer A, Flessa S. Cost comparison of MRSA screening and management - a decision tree analysis. BMC Health Serv Res. 2012;12:438.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Lee BY, Bailey RR, Smith KJ, Muder RR, Strotmeyer ES, Lewis GJ, et al. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect Control Hosp Epidemiol. 2010;31(6):598–606.Google Scholar
  13. KRINKO. Commission for Hospital Hygiene and Infection Prevention at the Robert-Koch Institute: Empfehlungen zur Prävention und Kontrolle von Methicillin-resistenten Staphylococcus aureus-Stämmen (MRSA) in medizinischen und pflegerischen Einrichtungen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:696–732. [in German].Google Scholar
  14. Tubbicke A, Hubner C, Kramer A, Hubner NO, Flessa S. Transmission rates, screening methods and costs of MRSA--a systematic literature review related to the prevalence in Germany. Eur J Clin Microbiol Infect Dis. 2012;31(10):2497–511.View ArticlePubMedGoogle Scholar
  15. Geffers C, Barry MF. Risk of transmission of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) from patients colonized with MRSA. Infect Control Hosp Epidemiol. 2005;26(02):114–5.View ArticlePubMedGoogle Scholar
  16. Safdar N, Marx J, Meyer NA, Maki DG. Effectiveness of preemptive barrier precautions in controlling nosocomial colonization and infection by methicillin-resistant Staphylococcus aureus in a burn unit. Am J Infect Control. 2006;34(8):476–83.View ArticlePubMedGoogle Scholar
  17. Worby CJ, Jeyaratnam D, Robotham JV, Kypraios T, O'Neill PD, De Angelis D, et al. Estimating the effectiveness of isolation and decolonization measures in reducing transmission of methicillin-resistant Staphylococcus aureus in hospital general wards. Am J Epidemiol. 2013;177(11):1306–13.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM. Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol. 1996;143(5):496–504.View ArticlePubMedGoogle Scholar
  19. Raboud J, Saskin R, Simor A, Loeb M, Green K, Low DE, et al. Modeling transmission of methicillin-resistant Staphylococcus aureus among patients admitted to a hospital. Infect Control Hosp Epidemiol. 2005;26(7):607–15.View ArticlePubMedGoogle Scholar
  20. Creamer E, Galvin S, Dolan A, Sherlock O, Dimitrov BD, Fitzgerald-Hughes D, et al. Evaluation of screening risk and nonrisk patients for methicillin-resistant Staphylococcus aureus on admission in an acute care hospital. Am J Infect Control. 2012;40(5):411–5.View ArticlePubMedGoogle Scholar
  21. Buhlmann M, Bogli-Stuber K, Droz S, Muhlemann K. Rapid screening for carriage of methicillin-resistant Staphylococcus aureus by PCR and associated costs. J Clin Microbiol. 2008;46(7):2151–4.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Shenoy ES, Kim J, Rosenberg ES, Cotter JA, Lee H, Walensky RP, et al. Discontinuation of contact precautions for methicillin-resistant staphylococcus aureus: a randomized controlled trial comparing passive and active screening with culture and polymerase chain reaction. Clin Infect Dis. 2013;57(2):176–84.PubMed CentralView ArticlePubMedGoogle Scholar
  23. McKinnell JA, Huang SS, Eells SJ, Cui E, Miller LG. Quantifying the impact of extranasal testing of body sites for methicillin-resistant Staphylococcus aureus colonization at the time of hospital or intensive care unit admission. Infect Control Hosp Epidemiol. 2013;34(2):161–70.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Hübner et al. 2015

Advertisement